Market Place
Sourcing Support
Yumanity Declares Special Dividend In Connection with Proposed Asset Sale
05 Dec 2022 //
GLOBENEWSWIRE
Yumanity Therapeutics Reports 3Q 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Yumanity Therapeutics Announces Effectiveness of Registration Statement
10 Nov 2022 //
GLOBENEWSWIRE
Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4
29 Aug 2022 //
GLOBENEWSWIRE
Yumanity Therapeutics Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Yumanity Announces Definitive Agreements for Two Strategic Transactions
06 Jun 2022 //
GLOBENEWSWIRE
Yumanity Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Yumanity Tx Reports Full-Year 2021 Financial Results and Corporate Developments
24 Mar 2022 //
GLOBENEWSWIRE
Yumanity to cut 60% of workforce by April, looking for buyers
18 Feb 2022 //
FIERCEBIOTECH
Yumanity Tx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Feb 2022 //
GLOBENEWSWIRE
Yumanity, continues its backslide as lead program earns a partial hold
20 Jan 2022 //
ENDPTS
Yumanity’s Approach to Neurodegenerative Diseases Validated
11 Jan 2022 //
GLOBENEWSWIRE
Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference
04 Jan 2022 //
GLOBENEWSWIRE
Yumanity Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Nov 2021 //
GLOBENEWSWIRE
Yumanity Announces Positive Top-Line Results of Phase 1b Trial for YTX-7739
10 Nov 2021 //
GLOBENEWSWIRE
Yumanity Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09 Sep 2021 //
GLOBENEWSWIRE
Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer
16 Aug 2021 //
GLOBENEWSWIRE
Yumanity Therapeutics to Present at the BTIG Virtual Biotechnology Conference
06 Aug 2021 //
GLOBENEWSWIRE
Yumanity Therapeutics’ R&D Day Reviews Near-Term Value Drivers
17 May 2021 //
GLOBENEWSWIRE
Yumanity Therapeutics’ YTX-7739 Achieved Target Engagement at Doses
22 Apr 2021 //
GLOBENEWSWIRE
Yumanity Announces Study Demonstrating In Vivo Efficacy of YTX-7739
06 Apr 2021 //
GLOBENEWSWIRE
Yumanity ’ YTX-7739 Demonstrates Prevention of Motor Function
09 Mar 2021 //
GLOBENEWSWIRE
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
23 Dec 2020 //
GLOBENEWSWIRE
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
23 Dec 2020 //
GLOBENEWSWIRE
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
23 Aug 2020 //
BIOSPACE
Yumanity snags a CMO as Shire keeps bleeding execs
18 Nov 2019 //
FIERCE BIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.